Common activation mechanism of class A GPCRs
Class A G-protein-coupled receptors (GPCRs) influence virtually every aspect of human physiology. Understanding receptor activation mechanism is critical for discovering novel therapeutics since about one-third of all marketed drugs target members of this family. GPCR activation is an allosteric pro...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
eLife Sciences Publications Ltd
2019-12-01
|
Series: | eLife |
Subjects: | |
Online Access: | https://elifesciences.org/articles/50279 |
id |
doaj-1fd7d071b55047e5a53a68b7fcb67b21 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Qingtong Zhou Dehua Yang Meng Wu Yu Guo Wanjing Guo Li Zhong Xiaoqing Cai Antao Dai Wonjo Jang Eugene I Shakhnovich Zhi-Jie Liu Raymond C Stevens Nevin A Lambert M Madan Babu Ming-Wei Wang Suwen Zhao |
spellingShingle |
Qingtong Zhou Dehua Yang Meng Wu Yu Guo Wanjing Guo Li Zhong Xiaoqing Cai Antao Dai Wonjo Jang Eugene I Shakhnovich Zhi-Jie Liu Raymond C Stevens Nevin A Lambert M Madan Babu Ming-Wei Wang Suwen Zhao Common activation mechanism of class A GPCRs eLife allostery GPCR activation mechanism genetic diseases signal transduction drug discovery |
author_facet |
Qingtong Zhou Dehua Yang Meng Wu Yu Guo Wanjing Guo Li Zhong Xiaoqing Cai Antao Dai Wonjo Jang Eugene I Shakhnovich Zhi-Jie Liu Raymond C Stevens Nevin A Lambert M Madan Babu Ming-Wei Wang Suwen Zhao |
author_sort |
Qingtong Zhou |
title |
Common activation mechanism of class A GPCRs |
title_short |
Common activation mechanism of class A GPCRs |
title_full |
Common activation mechanism of class A GPCRs |
title_fullStr |
Common activation mechanism of class A GPCRs |
title_full_unstemmed |
Common activation mechanism of class A GPCRs |
title_sort |
common activation mechanism of class a gpcrs |
publisher |
eLife Sciences Publications Ltd |
series |
eLife |
issn |
2050-084X |
publishDate |
2019-12-01 |
description |
Class A G-protein-coupled receptors (GPCRs) influence virtually every aspect of human physiology. Understanding receptor activation mechanism is critical for discovering novel therapeutics since about one-third of all marketed drugs target members of this family. GPCR activation is an allosteric process that couples agonist binding to G-protein recruitment, with the hallmark outward movement of transmembrane helix 6 (TM6). However, what leads to TM6 movement and the key residue level changes of this movement remain less well understood. Here, we report a framework to quantify conformational changes. By analyzing the conformational changes in 234 structures from 45 class A GPCRs, we discovered a common GPCR activation pathway comprising of 34 residue pairs and 35 residues. The pathway unifies previous findings into a common activation mechanism and strings together the scattered key motifs such as CWxP, DRY, Na+ pocket, NPxxY and PIF, thereby directly linking the bottom of ligand-binding pocket with G-protein coupling region. Site-directed mutagenesis experiments support this proposition and reveal that rational mutations of residues in this pathway can be used to obtain receptors that are constitutively active or inactive. The common activation pathway provides the mechanistic interpretation of constitutively activating, inactivating and disease mutations. As a module responsible for activation, the common pathway allows for decoupling of the evolution of the ligand binding site and G-protein-binding region. Such an architecture might have facilitated GPCRs to emerge as a highly successful family of proteins for signal transduction in nature. |
topic |
allostery GPCR activation mechanism genetic diseases signal transduction drug discovery |
url |
https://elifesciences.org/articles/50279 |
work_keys_str_mv |
AT qingtongzhou commonactivationmechanismofclassagpcrs AT dehuayang commonactivationmechanismofclassagpcrs AT mengwu commonactivationmechanismofclassagpcrs AT yuguo commonactivationmechanismofclassagpcrs AT wanjingguo commonactivationmechanismofclassagpcrs AT lizhong commonactivationmechanismofclassagpcrs AT xiaoqingcai commonactivationmechanismofclassagpcrs AT antaodai commonactivationmechanismofclassagpcrs AT wonjojang commonactivationmechanismofclassagpcrs AT eugeneishakhnovich commonactivationmechanismofclassagpcrs AT zhijieliu commonactivationmechanismofclassagpcrs AT raymondcstevens commonactivationmechanismofclassagpcrs AT nevinalambert commonactivationmechanismofclassagpcrs AT mmadanbabu commonactivationmechanismofclassagpcrs AT mingweiwang commonactivationmechanismofclassagpcrs AT suwenzhao commonactivationmechanismofclassagpcrs |
_version_ |
1721458707636682752 |
spelling |
doaj-1fd7d071b55047e5a53a68b7fcb67b212021-05-05T18:12:10ZengeLife Sciences Publications LtdeLife2050-084X2019-12-01810.7554/eLife.50279Common activation mechanism of class A GPCRsQingtong Zhou0https://orcid.org/0000-0001-8124-3079Dehua Yang1https://orcid.org/0000-0003-3028-3243Meng Wu2Yu Guo3Wanjing Guo4Li Zhong5Xiaoqing Cai6Antao Dai7Wonjo Jang8Eugene I Shakhnovich9https://orcid.org/0000-0002-4769-2265Zhi-Jie Liu10https://orcid.org/0000-0001-7279-2893Raymond C Stevens11Nevin A Lambert12https://orcid.org/0000-0001-7550-0921M Madan Babu13Ming-Wei Wang14Suwen Zhao15https://orcid.org/0000-0001-5609-434XiHuman Institute, ShanghaiTech University, Shanghai, ChinaThe CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China; University of Chinese Academy of Sciences, Beijing, China; The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, ChinaiHuman Institute, ShanghaiTech University, Shanghai, China; University of Chinese Academy of Sciences, Beijing, China; School of Life Science and Technology, ShanghaiTech University, Shanghai, ChinaiHuman Institute, ShanghaiTech University, Shanghai, China; University of Chinese Academy of Sciences, Beijing, China; School of Life Science and Technology, ShanghaiTech University, Shanghai, ChinaThe CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China; University of Chinese Academy of Sciences, Beijing, China; The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, ChinaThe CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China; University of Chinese Academy of Sciences, Beijing, China; The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, ChinaThe CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China; The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, ChinaThe CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China; The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, ChinaDepartment of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, United StatesDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, United StatesiHuman Institute, ShanghaiTech University, Shanghai, China; School of Life Science and Technology, ShanghaiTech University, Shanghai, ChinaiHuman Institute, ShanghaiTech University, Shanghai, China; School of Life Science and Technology, ShanghaiTech University, Shanghai, ChinaDepartment of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, United StatesMRC Laboratory of Molecular Biology, Cambridge, United KingdomThe CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China; University of Chinese Academy of Sciences, Beijing, China; The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China; School of Life Science and Technology, ShanghaiTech University, Shanghai, China; School of Pharmacy, Fudan University, Shanghai, ChinaiHuman Institute, ShanghaiTech University, Shanghai, China; School of Life Science and Technology, ShanghaiTech University, Shanghai, ChinaClass A G-protein-coupled receptors (GPCRs) influence virtually every aspect of human physiology. Understanding receptor activation mechanism is critical for discovering novel therapeutics since about one-third of all marketed drugs target members of this family. GPCR activation is an allosteric process that couples agonist binding to G-protein recruitment, with the hallmark outward movement of transmembrane helix 6 (TM6). However, what leads to TM6 movement and the key residue level changes of this movement remain less well understood. Here, we report a framework to quantify conformational changes. By analyzing the conformational changes in 234 structures from 45 class A GPCRs, we discovered a common GPCR activation pathway comprising of 34 residue pairs and 35 residues. The pathway unifies previous findings into a common activation mechanism and strings together the scattered key motifs such as CWxP, DRY, Na+ pocket, NPxxY and PIF, thereby directly linking the bottom of ligand-binding pocket with G-protein coupling region. Site-directed mutagenesis experiments support this proposition and reveal that rational mutations of residues in this pathway can be used to obtain receptors that are constitutively active or inactive. The common activation pathway provides the mechanistic interpretation of constitutively activating, inactivating and disease mutations. As a module responsible for activation, the common pathway allows for decoupling of the evolution of the ligand binding site and G-protein-binding region. Such an architecture might have facilitated GPCRs to emerge as a highly successful family of proteins for signal transduction in nature.https://elifesciences.org/articles/50279allosteryGPCRactivation mechanismgenetic diseasessignal transductiondrug discovery |